Categories
Change Password!
Reset Password!
An exploratory randomized controlled trial (RCT) determined the therapeutic potential and safety of Latilactobacillus sakei LB-P12 in knee osteoarthritis (OA).
Daily supplementation with Latilactobacillus sakei LB-P12 effectively reduces knee pain, inflammation, and functional limitations in knee osteoarthritis.
An exploratory randomized controlled trial (RCT) determined the therapeutic potential and safety of Latilactobacillus sakei LB-P12 in knee osteoarthritis (OA).
In this double-blind, placebo-controlled study, 100 adults (aged 40–75 years) with chronic knee pain received either LB-P12 (350 mg/day, containing 10 billion colony-forming unit) or placebo for 12 weeks. The key endpoint was betterment in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.
Secondary outcomes assessed pain via the visual analog scale (VAS), inflammatory markers (C-reactive protein, erythrocyte sedimentation rate, interleukin [IL]-1β, IL-6, tumor necrosis factor-α), cartilage degradation biomarkers, joint space width, and quality of life (EuroQol 5-Dimension 5-Level [EQ-5D-5L]).
After 12 weeks, the LB-P12 group illustrated remarkably greater improvements in total WOMAC and VAS pain scores when compared to placebo. Reductions were consistent across all WOMAC subdomains—pain, stiffness, and physical function. Notably, inflammatory cytokines, especially IL-1β, considerably dropped in the probiotic group, while participants also reported improved quality of life. No deleterious adverse events or aberrant lab findings were noted.
Probiotic Latilactobacillus sakei LB-P12 was safe and exhibited clinically meaningful benefits in reducing pain and improving joint function in knee OA. However, larger and longer-term RCTs are warranted to confirm its clinical potency and uncover underlying mechanisms.
Scientific Reports
Efficacy and safety of Latilactobacillus sakei LB-P12 in patients with knee osteoarthritis: an exploratory randomized, double-blind, placebo-controlled clinical trial
Bo-Kyung Shine et al.
Comments (0)